hrp0084p3-847 | Fat | ESPE2015

Uric Acid and Triglycerides/HDL Ratio as a Predisposing Factor for Metabolic Syndrome in Children

Katsa Maria Efthymia , Ioannidis Anastasios , Zyga Sofia , Tsironi Maria , Koutsovitis Paraskevas , Sachlas Athanasios , Kolovos Petros , Magana Maria , Daratsianou Maria , Paola Andrea , Gil Rojas

Background: Uric acid and Triglycerides/HDL ratio are an important risk factor for cardiovascular diseases.Aim: To investigate how Triglycerides/HDL ratio and uric acid are correlated with children’s biochemical and anthropometric characteristics, depending on the predisposition for metabolic syndrome (MetSyn).Methods: 110 students, 6–12 years old, living in Sparta-Greece, participated in our research. Anthropometric and ...

hrp0084p3-854 | Fat | ESPE2015

Association of Sleep Habits and Risk Factors for Metabolic Disorders in Children

Magana Maria , Zyga Sofia , Ioannidis Anastasios , Sachlas Athanasios , Katsa Maria Efthymia , Pistikou Anna Maria , Dimoliani Dafni Eleni Kougioumtzi , Daratsianou Maria , Kolovos Petros , Gil Andrea Paola Rojas

Background: Sleep is a complex and essential biological process that is required on a daily basis for all humans, playing a vital role in the maintenance of the homeostasis in short and long term.Aims and objectives: To investigate the role of sleep hours in correlation with risk factors for metabolic disorders in a children population.Methods: The program was implemented in 949 children (5–12 years old) living in Sparta-Greec...

hrp0084p3-977 | GH & IGF | ESPE2015

Congenital Hypopituitarism and Severe Developmental Delay Associated with Homozygous POU1F1 Mutation

Melikian Maria , Tiulpakov Anatoly , Gavrilova Anna

Background: Mutations in POU1F1 is a rare cause of combined pituitary hormone deficiency, which commonly includes GH, TSH and prolactin deficiencies and characterised by hypoplastic anterior pituitary.Objective and hypotheses: To present a case of severe short stature and developmental delay 1.5 years old girl, who was admitted to our hospital because of short stature.Method: Hypopituitarism panel’ genes were sequence...

hrp0084p3-1091 | Perinatal | ESPE2015

Transient Neonatal Hypoparathyroidism Secondary to an Unknown Maternal Parathyroid Adenoma

Teresa Perez Maria , Regina Labra , Ana Llorente

Background: Transient neonatal hypoparathyroidism (hPT) by inhibition of fetal parathyroid secondary to undiagnosed asymptomatic hyperparathyroidism (HPT) in the mother often debuts as late neonatal seizures.Objective and hypotheses: To emphasise the indication of maternal metabolic study (Cacium-Ca-, Phosphorus-P- and PTH) in addressing late neonatal hypocalcemia, especially in the case of late neonatal hypocalcemic seizures.Metho...

hrp0094p2-149 | Diabetes and insulin | ESPE2021

Assessment of the percentage of T lymphocytes and B lymphocytes with the expression of selected activation markers in patients with type 1 diabetes mellitus depending on the presence of antibodies against EBV antigens.

Rysz Izabela , Hymos Anna , Klatka Maria ,

Introduction: After contact with the antigen, lymphocytes require activation for proliferation and differentiation into effector cells. Activation of lymphocytes results in the expression of activation markers. The CD69 antigen appears first on the surface of lymphocytes. This occurs one hour after receiving the activation signal. The CD69 molecule acts as a cellular stimulating signal, causing further activation and proliferation of cells, stimulating the syn...

hrp0094p2-327 | Growth and syndromes (to include Turner syndrome) | ESPE2021

A case of a Floating-Harbor syndrome in a child with severe short stature.

Prosvirnina Anna , Bolmasova Anna , Melikyan Maria ,

Introduction: Floating-Harbor syndrome is a rare autosomal dominant genetic disorder caused by mutations in SRCAP gene. This condition is characterized by dysmorphic facial features, short stature and expressive language delay. Here we present a clinical case of a child with Floating-Harbor syndrome.Clinical case: A girl to consanguineous healthy parents was born at 37 gestation weeks with height 47 cm (SDS=-0,46) and weight 224...

hrp0097p1-87 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

A novel CACNA1D mutation leading to severe diazoxide unresponsive CHI

Melikyan Maria , Gubaeva Diliara , Novokreschennih Evgeniya

Introduction: Approximately 25% of congenital hyperinsulinism (CHI) patients are unresponsive to medical therapy. These cases are usually associated with inactivating ABCC8/KCNJ11 genes mutations or rarely with dominant GCK variants. Activating dominant mutations in the CACNA1D gene were recently found to cause mild form of CHI, muscle hypotonia and autistic features.Objectives: Herein we descr...

hrp0097p1-295 | GH and IGFs | ESPE2023

Sex steroid priming decreases the frequency of divergent results between spontaneous and stimulated GH tests

Lennartsson Otto , Nilsson Ola , Lodefalk Maria

Introduction: The diagnosis of growth hormone (GH) deficiency (GHD) is complicated by the low specificity of GH testing, especially in children before and during early pubertal stages. Sex steroid priming reduces false positive results in pre- and early pubertal children. However, only a small number of studies have assessed its efficacy in improving the diagnostic accuracy of GHD investigations.Aim: To evaluate the effe...

hrp0092fc2.3 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Higher Dose of Burosumab is Needed for Treatment of Children with Severe Forms of X-Linked Hypophosphatemia

Zhukouskaya Volha , Audrain Christelle , Lambert Anne-Sophie , Kamenicky Peter , Adamsbaum Catherine , Nevoux Jerome , Chaussain Catherine , Wicart Philippe , Briot Karine , Di Rocco Federico , Colao Annamaria , Di Somma Carolina , Trabado Séverine , Prié Dominique , Rothenbuhler Anya , Linglart Agnès

Background/Aim: X-linked hypophosphatemia (XLH) is a rare disease caused by mutations in PHEX, leading to elevated FGF23 levels, hypophosphatemia and chronic renal phosphate wasting. Burosumab is a monoclonal antibody against anti-FGF23, which has been recently approved for treatment of XLH. Beyond clinical trials, little is known about its efficacy/safety in clinical practice which is the aim of study.Patients/Methods: ...

hrp0092p1-23 | Bone, Growth Plate and Mineral Metabolism | ESPE2019

Increased Prevalence of Overweight and Obesity and its Clinical Predictors in Children Affected by X-Linked Hypophosphatemia

Zhukouskaya Volha , Rothenbuhler Anya , Colao Annamaria , Di Somma Carolina , Kamenicky Peter , Trabado Séverine , Prié Dominique , Audrain Christelle , Barosi Anna , Kyheng Christèle , Lambert Anne-Sophie , Linglart Agnès

Background/Aim: X-linked hypophosphatemia (XLH) is a rare disease caused by inactivating mutations in the phosphate-regulating endopeptidase homolog X-linked (PHEX) gene, characterized by chronic hypophosphatemia. XLH children present with progressive skeletal deformities (leg bowing, waddling gait, poor growth and disproportional short stature), dental abscesses, and craniosynostosis. Most affected children have been treated so far with multiple dail...